EXPERIENCE OF ADALIMUMAB ADMINISTRATION TO A PATIENT WITH JUVENILE ANKYLOSING SPONDYLOARTHRITIS AND CHRONIC VIRUS HEPATITIS B

The article presents a clinical case of high effectiveness of adalimumab — human monoclonal antibodies to tumor necrosis factor — in a patient with juvenile ankylosing spondyloarthritis refractory to therapy with classic immunosuppressive drugs and secondary to virus hepatitis B in the integrative phase. Joint pains and intensity of exudative alterations in interphalangeal and wrist joints attenuated as early as after as the first adalimumab injection; the authors achieved a 50% improvement in indices BASDAI (2.4) and ASDAI (1.1). Acute inflammatory alterations terminated, motion range of the affected joints completely recovered, general laboratory parameters of disease activity (erythrocyte sedimentation rate, C-reactive protein and white blood cell count) normalized and inactive disease stage was registered after 6 months. Adverse events or virus hepatitis B exacerbations in the setting of adalimumab therapy were not observed. No osteochondral destruction progression was observed at computed and magnetic resonance imaging of joints 6 months after the therapy beginning. Emotional condition and quality of life of the child and his family improved considerably.

1. Nikishina I.P., Kuz'mina N.N. Vestnik Rossiiskoi akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2008; 6: 41−8.

2. Nikishina I.P., Malievskii V.A., Fedorov E.S., Pervushina E.P., Nuriakhmetova A.Zh. Voprosy sovremennoi pediatrii = Current pediatrics. 2011; 3: 170−4.

3. Fetisova A.N., Alekseeva E.I., Bzarova T.M., Sleptsova T.V. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 2: 131−8.

4. Godzenko A.A., Korsakova Yu.L., Badokin V.V. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2012; 2: 66−76.

5. Zinchuk I.Yu. Farmateka = Pharmateca. 2014; 7: 77−82.

6. Simpson K., Marlou N., Shou Dzh., Rudakova A.V. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 4: 53−58.

7. Balykova L.A., Ivyanskaya N.V., Arzamaskina T.N., Makarkina E.V., Lavskaya Ya.V. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 6: 93−97.

8. Galstyan L.A., Zholobova E.S., Rozvadovskaya O.S., Bunin A.V., Starikova A.V. Voprosy sovremennoi pediatrii = Current pediatrics. 2012; 6: 142−146.

9. Denisova R.V., Alekseeva E.I., Isaeva K.B., Sleptsova T.V., Bzarova T.M., Valieva S.I., Mitenko E.V., Chistyakova E.G., Chomakhidze A.M., Fetisova A.N., Lomakina O.L. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 6: 123−9.

10. Alekseeva E.I., Isaeva K.B., Denisova R.V., Sleptsova T.V., Valieva S.I., Bzarova T.M., Mitenko E.V., Chomakhidze A.M. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 4: 149−153.

11. Schiff M.H., Breedveld F.C., Weisman M.H. Ann Rheum Dis. 2005; 64 (Suppl. III): 438.

12. Kievit W., Adang E.M., Fransen J. ARD Online First, published on January 3, 2008 as 10.1136/ard.2007.083675.

13. Vermeer M., Kuper H.H., Bernelot M.H., Hoekstra M., Posthumus M.D. Arthritis Research Therapy. 2012; 14: R254.

14. Kozlova A.L., Alekseeva E.I., Isaeva K.B., Bzarova T.M., Valieva S.I., Gudkova E.Yu., Chomakhidze A.M., Denisova R.V., Lisitsyn A.O., Sleptsova T.V. Voprosy sovremennoi pediatrii = Current pediatrics. 2010; 2: 23−31.